A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Latest Information Update: 22 Apr 2025
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 18 Apr 2025 Status changed from active, no longer recruiting to completed.
- 11 Apr 2025 Planned End Date changed from 13 Jun 2026 to 3 Feb 2026.
- 11 Apr 2025 Planned primary completion date changed from 13 Dec 2025 to 3 Feb 2026.